Clever Culture Systems Partnered With PSC Biotech
The firms have signed a deal to sell automated AI culture plate reading technology in three major markets.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you trust that outsourcing quality testing to third-party firms improves pharmaceutical manufacturing safety?
Clever Culture Systems has appointed PSC Biotech as its sales agent for the APAS Independence platform across the US, Canada, and Singapore. The partnership seeks to introduce this automated, FDA-cleared AI technology to regional and mid-tier pharmaceutical manufacturing firms.
Why it matters
By leveraging PSC Biotech's established client base, Clever Culture Systems aims to scale its market reach beyond major current customers like Pfizer and AstraZeneca. The deal focuses on penetrating sectors that traditionally rely on manual processes for culture plate reading.
The APAS Independence platform utilizes FDA-cleared AI technology to provide automated culture plate reading capabilities. PSC Biotech intends to showcase this hardware by installing an instrument at its new Pennsylvania center of excellence.
The players
Clever Culture Systems
This biotechnology company specializes in automated microbiology solutions, including the FDA-cleared APAS Independence platform.
PSC Biotech
This firm provides professional services to the life sciences industry and serves over 1,000 customers globally with a workforce of 500 employees.
The details
PSC Biotech will identify and refer sales opportunities for the platform, while Clever Culture Systems will maintain control over pricing and closing contracts. The company plans to increase its qualified sales pipeline over the next 12 months as it establishes its presence in the Pennsylvania facility.
Timeline
October 14, 2026: The partnership agreement was officially announced.
Over the next 12 months: The companies expect to increase qualified sales opportunities.
36 months: This represents the initial term of the sales agent agreement.
FY28 and beyond: Instrument sales conversions are expected to begin during this timeframe.
The Tech Race
This deal underscores the broader industrial shift toward automating manual laboratory processes using AI-driven diagnostic tools. By moving these capabilities into mid-tier manufacturing, the companies are accelerating the obsolescence of traditional, labor-intensive manual plate screening.
Mid-tier pharmaceutical manufacturers may soon gain access to AI-driven automation that reduces the reliance on manual labor for culture plate analysis. This technology could ultimately standardize testing workflows and improve speed for drug development processes across these facilities.
The takeaway
The move represents a strategic expansion for biotech automation providers targeting smaller manufacturing markets. Companies implementing these AI systems should prepare for shifts in laboratory staffing requirements as automated hardware replaces traditional manual observation methods.
Further reading
Learn more about the latest innovations in the Biotech sector.
Live Poll
Do you trust that outsourcing quality testing to third-party firms improves pharmaceutical manufacturing safety?
